Post by icemandios on Mar 2, 2024 3:22:49 GMT
On February 28, 2024, Cocrystal Pharma, Inc. (the “Company”) provided notice to Kansas State University Research Foundation of the Company’s election to terminate the License Agreements (the “Agreements”) dated February 12, 2020 and April 19, 2020. The terminations, which were made due to the Company’s determination that further development efforts under the Agreements would be futile, are effective on March 29, 2024. The material terms of the Agreements are summarized in the Company’s previous Current Reports on Form 8-K filed on February 24, 2020 and April 22, 2020, which descriptions are incorporated herein by reference.
The Company has developed under its proprietary structure-based drug discovery platform technology the wholly owned compound CDI-988 as a pan-viral therapeutic for coronavirus and norovirus, which compound is not affected by the terminations described above. CDI-988 is currently progressing in a Phase 1 clinical trial.
The Company has developed under its proprietary structure-based drug discovery platform technology the wholly owned compound CDI-988 as a pan-viral therapeutic for coronavirus and norovirus, which compound is not affected by the terminations described above. CDI-988 is currently progressing in a Phase 1 clinical trial.